MedPath

Pediatric -Adult Care Transition Program of Patients With Sickle Cell Disease

Not Applicable
Recruiting
Conditions
Sickle Cell Disease
Interventions
Other: pediatric-adult care transition program
Registration Number
NCT03786549
Lead Sponsor
Hospices Civils de Lyon
Brief Summary

Background The pediatric-adult care transition is a risk-disrupting time for patients with chronic disease. This care transition takes place during adolescence; a period of psychological upheavals and adaptations of family roles. During this period, medication adherence is non-optimal and absenteeism at medical appointments is high.

Sickle cell disease (SCD) is the first genetic disease detected in France. It is chronic disease characterized by frequent painful vaso-occlusive crises (VOC) requiring emergency hospitalization when they are severe. Other serious complications are acute chest syndromes (ACS) and stroke.

In order to improve the health status of teenagers with sickle cell disease, it is necessary to anticipate this care transition and to involve the pediatric and adult sectors. The biopsychosocial health approach and the Social-Ecological Model of Adolescent and Young Adult Readiness to Transition (SMART) describe a care transition integrating bioclinical and psychosocial factors such as integration of the patient's family, education on disease and therapeutics, psychological management of pain and medico-social orientation.

The pediatric-adult transition program proposed is based on this biopsychosocial approach. It aims to improve the health status of adolescents with SCD, their quality of life and the use of health care service.

Objective of the study To assess the impact of a pediatric-adult transition program on the incidence of sickle-cell-related complications leading to hospitalization on 24-months after transfer to the adult sector.

The evaluation focuses on severe complications leading to hospitalization, such as VOC, ACS, and stroke.

Study design Multicenter Open-label individual Randomized Controlled Trial Population : Patients aged at least 16 years old with sickle cell disease, and their parents (or legal representatives Number of subject : 196 patients (98 patients by arm) The study will last 24 months Expected results For patients and families Better health and quality of life for patients is expected, including better use of medical care after the transition program. It is also expected a better experience of the pediatric-adult care transition and indirectly a better experience of intrafamilial relations.

For health professionals This project is expected to provide solutions to improve the pediatric-adult care transition of patients with chronic disease. Indeed, the methodological quality of the study will make it possible to evaluate the efficiency of the proposed program, to possibly adapt it and test it to other chronic diseases presenting the same care transition problematic.

In terms of public health SCD mainly affects populations of sub-Saharan origin, with low visibility and high social vulnerability. By focusing on this population, this project will reduce the social inequalities in health, experienced by patients with SCD and their families.

By improving the health, quality of life and care of patients with SCD, this project is expected to decrease the cost of the pediatric-adult care transition period.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
196
Inclusion Criteria

For patients :

  • Age: 16-17 years,
  • With major sickle cell syndrome, defined by hemoglobinopathy of homozygosity SS, or double heterozygosity SC or Sβ-thalassemia,
  • Benefiting from social insurance of the type "Affection of long duration" (ALD).

For family members :

  • Included children's parents or legal representatives,
  • Accepting to participate in the study and having signed the informed consent.
Read More
Exclusion Criteria
  • Presenting a cognitive or psychiatric disorder known and major that may hinder interventions or evaluation, the judgment of the investigator, and / or having a family history with this type of disorders,
  • Cured of SCD by an allograft of hematopoietic stem cells.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Care transitional programpediatric-adult care transition programPatients included in this arm will get a care transitional program. Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent Three axes are : * Educative, family (patient and parent), at home * Psychological, with the patient individually * Medico-social orientation, group of patients
Primary Outcome Measures
NameTimeMethod
Incidence of sickle cell related severe complications leading to hospitalizationWithin 24 months after transfer to the adult sector

Number of hospital admission or emergency visit in the index hospital

Secondary Outcome Measures
NameTimeMethod
Medication Intake Survey-Asthma (MIS-A) questionnaire scoreAt inclusion

Medication adherence evaluation at inclusion

HLS-EU-Q16 scorewithin 24 months after transfer to the adult sector

Health Literacy evaluation within 24 months after transfer to the adult sector

Frequency of emergency visits in the index hospitalWithin 12 and 24 months after transfer to the adult sector
Medication Rating Scale (MARS) questionnaire scoreAt inclusion

Medication adherence evaluation at inclusion

MIS-A questionnaire scorewithin 24 months after transfer to the adult sector

Medication adherence evaluation within 24 months after transfer to the adult sector

Self efficacy specific instrument - sickle cell disease (SCD-SES) questionnaire scoreAt inclusion

Self efficacy evaluation at inclusion

MARS questionnaire scorewithin 24 months after transfer to the adult sector

Medication adherence evaluation within 24 months after transfer to the adult sector

Number of days absent at schoolwithin 24 months after transfer to the adult sector

Scholarly Absenteeism evaluation within 24 months after transfer to the adult sector

EUropean Health Literacy questionnaire (HLS-EU-Q16) scoreAt inclusion

This will allow Health Literacy evaluation

Patient activation measure-13 items questionnaire scorewithin 24 months after transfer to the adult sector

Patient activation within 24 months after transfer to the adult sector

number of pediatric-adult transition program sessions performedUp to 4 years

number of interventions performed per patient and date of implementation At the end of the study

World Health Organization Quality of Life (WHOQOL) questionnaire scoreAt inclusion

Quality of Life evaluation At inclusion

Disease knowledgewithin 24 months after transfer to the adult sector

Questionnaire developed for this study

SCD-SES questionnaire scorewithin 24 months after transfer to the adult sector

Self efficacy evaluation within 24 months after transfer to the adult sector

WHOQOL questionnaire scorewithin 24 months after transfer to the adult sector

Quality of Life evaluation within 24 months after transfer to the adult sector

Transition readiness assessment questionnaire (TRAQ) questionnaire scoreAt inclusion

Transition readiness evaluation at inclusion

type of pediatric-adult transition program sessions performedUp to 4 years

type of interventions performed per patient and date of implementation At the end of the study

TRAQ questionnaire scorewithin 24 months after transfer to the adult sector

Transition readiness evaluation within 24 months after transfer to the adult sector

cost effectiveness ratioUp to 4 years

Cost analysis at the end of the study

Trial Locations

Locations (8)

Centre Hospitalier de Pontoise

🇫🇷

Pontoise, France

CHU de Fort de France

🇫🇷

Fort-de-France-La Martinique, La Martinique, France

Centre Hospitalier Intercommunal de Creteil

🇫🇷

Créteil, France

Hôpital Mondor

🇫🇷

Créteil, France

Hôpital Bicêtre

🇫🇷

Le Kremlin-Bicêtre, France

Hôpital Necker

🇫🇷

Paris, France

Hospices Civils de Lyon

🇫🇷

Lyon, France

Hôpital Européen Georges Pompidou

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath